Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This emerging Bitcoin infrastructure company is building a vertically integrated model (click to learn more) Laser Photonics Announces Strategic Milestone on Advanced Laser Shield Anti Drone System (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Eton Pharmaceuticals Inc ETON

Healthcare Drug Manufacturers - Specialty & Generic
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.


NDAQ:ETON - Post by User

Eton Pharmaceuticals Inc
Bullboard Posts
Next >>
User Avatar Image
(10)
•••
  • MikeTesterX
Post by MikeTesteron Aug 02, 2024 9:32am
41 Views
Post# 36160443

Eton Pharmaceuticals, Inc. (NASDAQ:ETON): Delivering Consist

Eton Pharmaceuticals, Inc. (NASDAQ:ETON): Delivering Consisthttps://beyondspx.com/2024/08/01/eton-pharmaceuticals-inc-nasdaqeton-delivering-consistent-growth-and-advancing-late-stage-pipeline/
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities